We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 725

Cipla v Novartis: import qualifies as working of patent
  • LexOrbis
  • India
  • May 17 2017

The Indian pharmaceutical industry is a major manufacturer of cost-effective generic drugs and is set to become the leading exporter of generic


India: Trade dress and the importance of visual appearance
  • RNA IP Attorneys
  • India
  • May 1 2017

Marketers traditionally focus on designing advertising campaigns and other promotional strategies to promote a brand name. However, with evolving


Uncertainty remains over scope of value added products and biological resources
  • LexOrbis
  • India
  • April 26 2017

In recognition of India's rich biodiversity, the Biological Diversity Act 2002 is designed to help promote the sustainable use of its components, as


Monsanto Asserts no Government role in determining the Licensing Fee
  • RNA IP Attorneys
  • India
  • April 26 2017

The tug of war between Monsanto and its erstwhile licensees over licensing fee and Patent infringement continues unabated. The


Requirement of Bio-Equivalence Studies for Generic Drugs - a Step in the Right Direction
  • Khaitan & Co
  • India
  • April 25 2017

Access to affordable and safe medicines is the cornerstone of a vibrant public health framework. The cost of medicines substantially depends on the


CCI- Chemists and Druggists Associations Warned to Refrain from Indulging into Anti-Competitive Practices
  • SS Rana & Co
  • India
  • April 21 2017

In 2009, the Belgaum District Chemists and Druggists Association ('hereinafter referred as BCDA') filed a complaint alleging that Abbott India Ltd


Top 10 patent developments of 2016
  • RNA IP Attorneys
  • India
  • April 18 2017

This article summarizes key patent developments of 2016 including developments and initiatives by the Indian government to spread IP awareness and


Delhi High Court: Interpretation of ‘export’ under S. 107A of Patents Act, 1970
  • SS Rana & Co
  • India
  • April 10 2017

In a recent decision dated March 8, 2017 in Bayer Corporation v. Union of India & Ors; W.P.(C) 19712014 and Bayer Intellectual Property


Patent Wars - Round two in favour of Novartis as Cipla unable to mount credible challenge
  • RNA IP Attorneys
  • India
  • March 20 2017

The two judges bench (Division Bench) of the Delhi High Court has upheld the decision of a single judge restraining Cipla from selling generic


Compulsory licensing: law, challenges and strategies
  • LexOrbis
  • India
  • March 8 2017

The compulsory licensing provision is one of the most widely debated provisions of the Patents Act 1970 as it concerns the grant of a compulsory